Moderna Advances mRNA-Based Influenza Vaccine Development

Moderna, Inc. has announced continued backing from the U.S. Department of Health and Human Services (HHS) for the progression of mRNA-based pandemic influenza vaccines. The support, facilitated through the Rapid Response Partnership Vehicle Consortium, aims at advancing late-stage development and licensure of vaccines, backed by $590 million from the Biomedical Advanced Research and Development Authority (BARDA).

Moderna initiated a Phase 1/2 study of the pandemic influenza vaccine, mRNA-1018, targeting H5 and H7 avian influenza viruses in 2023. The promising initial results prompted plans to move mRNA-1018 into Phase 3 trials.

The funding will also facilitate expanded clinical trials on up to five additional influenza subtypes. The results from these studies will be shared at an upcoming scientific meeting.